130470 20240125162930.0 doi 10.23736/S0375-9393.20.14589-9 sideral 123344 ART-2021-123344 eng Serrano, A.B. Neuromuscular blockade management and postoperative outcomes in enhanced recovery colorectal surgery: secondary analysis of POWER trial 2021 BACKGROUND: We evaluated the impact of neuromuscular blockade (NMB) management, monitoring and reversal on postoperative outcomes in colorectal surgical patients included in an enhanced recovery program. METHODS: We performed a predefined analysis in 2084 patients undergoing elective colorectal surgery who participated in POWER study. We analyzed them for complications, length of hospital stay and mortality. Two groups were defined: 1) monitoring + reversal of the neuromuscular blockade (M+R) group: all patients receiving neuromuscular blockade monitoring plus reversal of it with any drug (neostigmine or sugammadex) were included; and 2) no monitoring nor reversal (noM+noR) group. In this group all the patients who did not receive monitoring and reversal of the neuromuscular blockade were allocated. RESULTS: Multivariate analysis found no statistically significant differences in moderate-severe complications (174 [25.7%] vs. 124 [27.1%]; P=0.607), length of hospital stay (10.8±11.1 vs. 11.0 ±12.6 days; P=0.683) and mortality (6 [0.9%] vs. 5 [1.1%]; P=0.840) between the group receiving optimal neuromuscular management (M+R) and the one did not receive it (noM+noR). Univariate analysis showed patients reversed with neostigmine died more than those reversed with sugammadex (3 [2.7%] vs. 3 [0.5%]; P=0.048). CONCLUSIONS: Our data suggest optimal neuromuscular blockade management in colorectal surgery is not associated with less moderate-severe complications, length of hospital stay or death during postoperative period in an enhanced recovery program. Neostigmine reversal seems to be linked to higher rate of mortality than sugammadex. info:eu-repo/semantics/closedAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 3.396 2021 CRITICAL CARE MEDICINE 20 / 35 = 0.571 2021 Q3 T2 ANESTHESIOLOGY 18 / 34 = 0.529 2021 Q3 T2 0.539 2021 Anesthesiology and Pain Medicine 2021 Q2 4.2 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Díaz-Cambronero, O. Melchor-Ripollés, J. Abad-Gurumeta, A. Ramírez-Rodríguez, J.M. Universidad de Zaragoza (orcid)0000-0001-7964-1166 Martínez-Ubieto, J. Universidad de Zaragoza (orcid)0000-0003-2462-1904 Sánchez-Merchante, M. Rodríguez, R. Jordá, L. Gil-Trujillo, S. Cabellos-Olivares, M. Bordonaba-Bosque, D. Universidad de Zaragoza (orcid)0000-0001-9444-606X Aldecoa, C. 1013 090 Universidad de Zaragoza Dpto. Cirugía Área Cirugía 4014 623 Universidad de Zaragoza Dpto. Economía Aplicada Área Métodos Cuant.Econ.Empres 87, 1 (2021), 13-25 Minerva anestesiol. Minerva Anestesiologica 0375-9393 487744 http://zaguan.unizar.es/record/130470/files/texto_completo.pdf Versión publicada 2624348 http://zaguan.unizar.es/record/130470/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:130470 articulos driver 2024-01-25-15:13:23 ARTICLE